The new NattoPharma USA, Inc. office and warehouse is up and running in East Brunswick, NJ.

New Brunswick (5 February 2021) After experiencing the highest recorded revenue in NattoPharma ASA’s history, the North American Subsidiary seamlessly shifted to a higher-capacity facility to better accommodate quicker turnaround times for customers and increased on-site personnel.   


 

About NattoPharma and MenaQ7®

NattoPharma ASA, based in Norway, is the world’s leader in vitamin K2 research and development. NattoPharma is the exclusive international supplier of MenaQ7® Vitamin K2 as MK-7, the best documented, vitamin K2 as menaquinone-7 (MK-7) with guaranteed actives and stability, clinical substantiation, and international patents granted and pending; and now the new MenaQ7® Full Spectrum, which delivers menaquinones 6, 7, and 9. The company has a multi-year research and development program to substantiate and discover the health benefits of Vitamin K2 for applications in the marketplace for functional food and dietary supplements. With a global presence, the company established its North American subsidiary, NattoPharma USA, Inc., in Edison, NJ, and NattoPharma R&D Ltd. in Cyprus. For more information, visit www.nattopharma.com or www.menaq7.com.

For more information, please contact:

Kate Quackenbush, NattoPharma Director of Communications

Phone: 609-643-0749 x 220

E-mail: kate.quackenbush@nattopharma.com